Completed PHASE3 NCT01846793

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart

Sponsor: Nymox Corporation

Conditions BPH Benign Prostatic Hyperplasia LUTS Lower Urinary Tract Symptoms (LUTS)

Interventions NX-1207

Updated 8 times since 2017 Last updated: Mar 9, 2017 Started: Apr 30, 2013 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

Listed as NCT01846793, this PHASE3 trial focuses on BPH and Benign Prostatic Hyperplasia and remains completed. Sponsored by Nymox Corporation, it has been updated 8 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Apr 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Apr 2017 — Jun 2018 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Feb 2017 — Apr 2017 [monthly]

Unknown Status PHASE3
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nymox Corporation

Data source: Nymox Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Annapolis, United States , Aventura, United States , Baltimore, United States , Brick, United States , Columbus, United States , Dallas, United States , Garden City, United States , Glen Burnie, United States , Jeffersonville, United States , Laguna Beach, United States and 7 more locations